Akron Participates in Newly Published Study Modelling Cost of Goods for Allogeneic CAR T

Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic

Upcoming Events – September 2018

As a scorching summer draws to a close and conference season begins, Akron will be participating at many upcoming events to further advocate for the use of higher quality ancillary materials in regenerative medicine processes.  Our focus of providing affordable cGMP reagents throughout the development stages for these unique therapeutics serves to better ensure reproducibility

FDA approves first gene therapy for hereditary disease — Spark Therapeutics’ Luxturna

On December 19, 2017, the US FDA approved a new gene therapy to treat children and adults with a genetic condition that often results in blindness. Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl) is a one-time gene therapy product that treats biallelic RPE65 mutation-associated retinal dystrophy, an inherited retinal disease that frequently progresses to complete blindness. Approval